Ferring Pharmaceuticals in the news

Krishnakumar N has been appointed as Director, External Manufacturing Network, Operational Stream Lead at Ferring Pharmaceuticals, overseeing the operational stream for the Asian region.

Ferring Pharmaceuticals surpassed €2.5 billion revenue in 2025, driven by key products and sustainability efforts, while improving cash flow and expanding access to healthcare.

Ferring Pharmaceuticals grew from $15 million to $2.2 billion in sales under Frederik Paulsen, specializing in various specialty biopharmaceutical drugs with a global presence.

Ferring Pharmaceuticals has partnered with Gallup to launch a 70-country study investigating the socio-economic drivers behind declining global birth rates.

RedHill Biopharma acquired global commercialization rights for two established gastrointestinal drugs, Rebyota and Clenpiq, from Ferring Pharmaceuticals for $12 million upfront, following the divestiture of Talicia.

RedHill Biopharma acquired two established gastrointestinal drugs, Rebyota and Clenpiq, from Ferring Pharmaceuticals, boosting its commercial portfolio with products that generated significant revenue in 2025.

Ferring Pharmaceuticals, a privately held biopharmaceutical company, has grown significantly by focusing on specialized therapeutic areas, decentralized management, and strong R&D investment, with a goal to lead in infertility treatments.

Ferring Pharmaceuticals is modernizing its scientific data management with a new informatics platform to enhance R&D, collaboration, and compliance.

The microbiome therapeutics market is forecast to grow significantly, driven by scientific advancements, regulatory approvals, and expanded clinical applications beyond C. difficile infection.

The microbiome therapeutics market is forecast to grow significantly, driven by scientific advancements, regulatory approvals, and strategic investments, with a shift towards standardized and precision-engineered therapies.

RedHill Pharmaceuticals is changing its business direction through a new in-licensing agreement with Ferring Pharmaceuticals and out-licensing deals with Apotex.

RedHill Biopharma acquired commercialization rights for Ferring's Rebyota and Clenpiq, two FDA-approved gastrointestinal drugs, for $12 million to expand its GI business.

RedHill Biopharma acquired global rights to Rebyota and U.S. rights to Clenpiq from Ferring Pharmaceuticals for $12 million upfront, expanding its gastrointestinal portfolio with products that generated $37.5 million in 2025 U.S. net sales.

RedHill Biopharma acquired commercialization rights for Rebyota and Clenpiq from Ferring Pharmaceuticals, boosting its gastrointestinal product portfolio.

RedHill Biopharma acquired global and US commercialization rights for Rebyota and Clenpiq from Ferring Pharmaceuticals, repositioning its GI business.

RedHill Biopharma acquired commercialization rights to Ferring's Rebyota and Clenpiq for $12 million, strengthening its GI business and liquidity.

RedHill Biopharma acquired the commercialization rights for two GI drugs, Rebyota and Clenpiq, from Ferring Pharmaceuticals for $12 million.

RedHill Biopharma acquired marketing rights for two gastrointestinal drugs, Rebyota and Clenpiq, from Ferring Pharmaceuticals for an upfront payment of $12 million.

RedHill Biopharma acquired commercialization rights for Rebyota and Clenpiq from Ferring Pharmaceuticals for $12 million, aiming to strengthen its gastrointestinal product portfolio and liquidity.

RedHill Biopharma acquired commercialization rights for Ferring Pharmaceuticals' Rebyota and Clenpiq, two FDA-approved gastrointestinal drugs, after divesting Talicia, to strategically reposition its GI business for growth and increased liquidity.